Pulmonx Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LUNG research report →
Companypulmonx.com
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves.
- CEO
- Glendon E. French
- IPO
- 2020
- Employees
- 291
- HQ
- Redwood City, CA, US
Price Chart
Valuation
- Market Cap
- $65.05M
- P/E
- -1.21
- P/S
- 0.73
- P/B
- 1.41
- EV/EBITDA
- -1.21
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 75.49%
- Op Margin
- -58.79%
- Net Margin
- -60.09%
- ROE
- -92.94%
- ROIC
- -50.83%
Growth & Income
- Revenue
- $90.50M · 8.01%
- Net Income
- $-54,003,000 · 4.24%
- EPS
- $-1.33 · 7.64%
- Op Income
- $-53,663,000
- FCF YoY
- 0.26%
Performance & Tape
- 52W High
- $3.88
- 52W Low
- $1.13
- 50D MA
- $1.37
- 200D MA
- $1.67
- Beta
- 0.18
- Avg Volume
- 553.77K
Get TickerSpark's AI analysis on LUNG
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 2, 26 | Radhakrishnan Srikanth | other | 175,000 |
| Mar 2, 26 | Radhakrishnan Srikanth | sell | 756 |
| Mar 2, 26 | Radhakrishnan Srikanth | sell | 3,068 |
| Mar 2, 26 | Radhakrishnan Srikanth | sell | 2,461 |
| Mar 2, 26 | Radhakrishnan Srikanth | sell | 4,198 |
| Mar 2, 26 | French Glendon E. III | sell | 2,708 |
| Mar 2, 26 | French Glendon E. III | sell | 6,737 |
| Mar 2, 26 | French Glendon E. III | sell | 58,368 |
| Mar 2, 26 | Rose Geoffrey Beran | other | 100,000 |
| Mar 2, 26 | Rose Geoffrey Beran | sell | 835 |
Our LUNG Coverage
We haven't published any research on LUNG yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LUNG Report →